reference/9950545

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9950545

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	240
issn	1592-8721 0390-6078
issueIdentifier	2
pageRange	232-240
publicationName	Haematologica
startingPage	232
bibliographicCitation	Shah NP, Kim D-, Kantarjian H, Rousselot P, Llacer PED, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Muller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb 01;95(2):232–40. doi: 10.3324/haematol.2009.011452.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2eea788aa83238365bf9edb6d6527a76 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_402e61fa655e8d537ac593d643470327 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d627a54ae2c79e65377c20abc6c385ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d78b481a4333b4519ee4d64ea98a3648 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d62d62a10663a29c8c28b85b0fa8c69 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_192a9392e69fa774dee0f14665862dcb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2a023f8ab25edae9c694030414831aa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fcbdc6a06c633fea265c5bdc8ea73b2d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd5740682941fb0dc52728d99f360c8f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d92064f91065958f33bb2e951f03f7d0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1abf8c487e1af71f409f5749887e6bd4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_46689dba6babb06934fbcb9e5c7a9aa2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a233633baf1804c1608f255ffb60a4d5
date	2010-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.3324/haematol.2009.011452 https://pubmed.ncbi.nlm.nih.gov/PMC2817025 https://pubmed.ncbi.nlm.nih.gov/20139391
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3942 https://portal.issn.org/resource/ISSN/0390-6078 https://portal.issn.org/resource/ISSN/1592-8721
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
discusses	http://id.nlm.nih.gov/mesh/M0002327 http://id.nlm.nih.gov/mesh/M0021333 http://id.nlm.nih.gov/mesh/M0470497 http://id.nlm.nih.gov/mesh/M0024527 http://id.nlm.nih.gov/mesh/M0018260 http://id.nlm.nih.gov/mesh/M0391958 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0016884 http://id.nlm.nih.gov/mesh/M0017888
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D047428Q000627 http://id.nlm.nih.gov/mesh/D016044Q000037 http://id.nlm.nih.gov/mesh/D015466Q000188 http://id.nlm.nih.gov/mesh/D010879Q000494 http://id.nlm.nih.gov/mesh/D011743Q000627 http://id.nlm.nih.gov/mesh/D011505Q000037 http://id.nlm.nih.gov/mesh/D011743Q000494 http://id.nlm.nih.gov/mesh/D013844Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D016044Q000378 http://id.nlm.nih.gov/mesh/D004351 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D011505Q000378 http://id.nlm.nih.gov/mesh/D011743Q000009 http://id.nlm.nih.gov/mesh/D013844Q000008 http://id.nlm.nih.gov/mesh/D001549 http://id.nlm.nih.gov/mesh/D000068877 http://id.nlm.nih.gov/mesh/D047428Q000008 http://id.nlm.nih.gov/mesh/D011743Q000008 http://id.nlm.nih.gov/mesh/D020732 http://id.nlm.nih.gov/mesh/D000069439 http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D010879Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3062316 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9729 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7055

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129879136 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128433595

Total number of triples: 71.